TPMT (thiopurine S-methyltransferase) is the primary enzyme responsible for inactivating thiopurine drugs¹¹ inactivating thiopurine drugs
These immunosuppressants include azathioprine, 6-mercaptopurine, and thioguanine, used to treat leukemia, inflammatory bowel disease, rheumatoid arthritis, and prevent organ transplant rejection. The TPMT*3C variant (rs1142345) is a no-function allele²² no-function allele
Produces an unstable enzyme with negligible activity that accounts for over 95% of TPMT deficiency cases in East Asian populations and is the predominant variant in individuals of African descent. This variant is one of three genetic markers covered by FDA labeling requirements³³ FDA labeling requirements
The FDA mandates that azathioprine drug labels include information about TPMT genetic testing for thiopurine drugs.

The Mechanism

The TPMT*3C allele results from an A-to-G substitution at position 719 in exon 10 of the TPMT gene, causing a tyrosine-to-cysteine amino acid change at position 240⁴⁴ tyrosine-to-cysteine amino acid change at position 240
p.Tyr240Cys disrupts protein folding (p.Tyr240Cys). This missense mutation produces a structurally unstable enzyme⁵⁵ structurally unstable enzyme
The mutant protein undergoes enhanced degradation via the ubiquitin-proteasome pathway with drastically reduced cellular protein levels and virtually no enzymatic activity. When TPMT cannot inactivate thiopurine drugs through methylation, these medications are shunted into pathways that generate toxic thioguanine nucleotides (TGNs)⁶⁶ thioguanine nucleotides (TGNs)
TGNs incorporate into DNA causing cell death; normally kept in check by TPMT methylation, leading to life-threatening bone marrow suppression.

The Evidence

A genome-wide association study of 1,026 children with leukemia⁷⁷ genome-wide association study of 1,026 children with leukemia
Liu et al. Genomewide approach validates thiopurine methyltransferase activity is a monogenic pharmacogenomic trait. Clin Pharmacol Ther. 2017 identified rs1142345 as the top hit (P = 8.6 × 10⁻⁶¹) for TPMT enzyme activity, with TPMT being the only gene to reach genome-wide significance. The Clinical Pharmacogenetics Implementation Consortium (CPIC)⁸⁸ Clinical Pharmacogenetics Implementation Consortium (CPIC)
Level A evidence - highest tier for clinical implementation has designated TPMT testing as having the strongest evidence for clinical utility, with specific dosing guidelines updated in 2025. Population studies reveal striking ethnic variation: TPMT*3C accounts for 100% of variant alleles in Chinese populations⁹⁹ 100% of variant alleles in Chinese populations
Collie-Duguid et al. found 4.7% of Chinese individuals carried TPMT*3C vs 0.5% in Caucasians. Pharmacogenetics 1999, 7.6% of alleles in Ghanaians, and 52.2% of variant alleles in African Americans, but only 0.17-0.3% in European populations.

Practical Implications

If you carry one or two copies of TPMT*3C, you are at risk for severe, potentially fatal bone marrow toxicity if given standard doses of thiopurine medications. Patients homozygous for TPMT deficiency alleles¹⁰¹⁰ Patients homozygous for TPMT deficiency alleles
About 0.3% of most populations, but varies by ancestry experience life-threatening myelosuppression on standard doses, while heterozygotes have intermediate risk. The CPIC guideline recommends 30-70% dose reduction for intermediate metabolizers (one variant allele) and 90% dose reduction or alternative therapy for poor metabolizers (two variant alleles). Critically, these recommendations are supported by the FDA, which includes TPMT status in drug labeling for azathioprine, mercaptopurine, and thioguanine.

Genetic testing before starting thiopurine therapy is considered essential for drug safety¹¹¹¹ considered essential for drug safety
Dutch Pharmacogenetics Working Group (DPWG) designates pre-treatment genotyping as essential by multiple international guidelines. If you require immunosuppression or chemotherapy, knowing your TPMT genotype allows your physician to either prescribe alternative medications (such as mycophenolate for transplant patients or methotrexate for inflammatory bowel disease) or adjust the dose appropriately with close monitoring.

Interactions

TPMT*3C commonly occurs together with TPMT*3B (rs1800460) to form the TPMT*3A compound allele, which is the most common variant in Caucasian populations. If you carry both rs1142345(G) and rs1800460(A), you likely have TPMT*3A rather than *3C alone, though this requires haplotype phasing¹²¹² haplotype phasing
Most clinical labs cannot distinguish whether variants are on the same chromosome (cis) or different chromosomes (trans) to confirm. The related gene NUDT15 (particularly rs116855232) also affects thiopurine metabolism and is more common in East Asians; individuals with variants in both TPMT and NUDT15 require even more substantial dose reductions.

A critical interaction occurs with xanthine oxidase inhibitors like allopurinol (used for gout). Since allopurinol blocks one pathway for inactivating thiopurines, combining it with reduced TPMT activity creates a double-blockade effect¹³¹³ double-blockade effect
FDA warns against allopurinol-azathioprine combination; if necessary, reduce azathioprine to 25% of standard dose that requires azathioprine dose reduction to 25% of normal or avoidance of the combination entirely.

Cathepsin S¹¹ Cathepsin S
A lysosomal cysteine protease encoded by CTSS on chromosome 1q21.3. It is expressed almost exclusively in professional antigen-presenting cells — dendritic cells, macrophages, and B cells — where it catalyses the final, rate-limiting step of MHC class II peptide loading sits at an unusual intersection: it is both an essential engine of adaptive immunity and, when expressed at elevated levels in the skin, a direct trigger of itch. A large-scale genome-wide association study meta-analysis identified rs115161931 as one of three independent genetic signals at the CTSS locus associated with atopic dermatitis (eczema), with each signal representing a distinct regulatory mechanism acting on the same gene.

rs115161931 is an intronic variant at chromosome 1:151,063,299 (GRCh38) within the CTSS chromosomal neighbourhood. The T allele is uncommon globally (~2.5%) but more prevalent in European populations (~4%), and is nearly absent in East Asian and African populations. Its effect on CTSS expression in primary immune cells has not yet been directly measured by eQTL studies, but the biological case for CTSS as the causal gene at this locus is strong: CTSS is the only gene in this region with established roles in both immune dysregulation and cutaneous itch.

The Mechanism

MHC class II molecules require a precise loading sequence before they can present antigens to CD4+ T helper cells. Newly assembled complexes in the endoplasmic reticulum are blocked by the invariant chain (Ii/CD74)²² invariant chain (Ii/CD74)
A chaperone protein that occupies the peptide-binding groove of MHC class II, directing the complex through the secretory pathway. In the lysosome it must be fully degraded before antigenic peptides can load. Cathepsin S is the specific enzyme responsible for the final Ii cleavage step — removing the CLIP fragment to expose the groove. Neither cathepsin B, H, nor D can substitute. Without sufficient cathepsin S, MHC class II complexes stall with the Ii fragment intact; with excess cathepsin S, antigen presentation is amplified, increasing the risk of priming autoreactive or hyperreactive T cells.

In the skin, cathepsin S has a second, independent mechanism of harm: extracellular secretion by skin-resident dendritic cells and keratinocytes, where it directly activates protease-activated receptor 2 (PAR2) on TRPV1-expressing sensory nerve endings³³ extracellular secretion by skin-resident dendritic cells and keratinocytes, where it directly activates protease-activated receptor 2 (PAR2) on TRPV1-expressing sensory nerve endings
PAR2 is a G-protein-coupled receptor that, when cleaved by cathepsin S, triggers downstream TRPV1 calcium signalling in nociceptors — producing itch independent of histamine. This histamine-independent itch pathway is mechanistically important because it explains why antihistamines are often inadequate for atopic dermatitis itch, and why CTSS inhibitors represent a distinct therapeutic target.

The Evidence

Budu-Aggrey et al. (Nature Communications, 2023)⁴⁴ Budu-Aggrey et al. (Nature Communications, 2023) conducted a multi-stage GWAS including 65,107 atopic dermatitis cases and 1,021,287 controls in the European discovery phase, subsequently expanded to a multi-ancestry cohort of 765,209 individuals and independently replicated in a 23andMe European cohort of 2,904,664 individuals. Twenty-nine novel atopic dermatitis loci were identified. The CTSS region yielded three independent signals — rs187080438, rs146527530, and rs115161931 — with this variant showing an odds ratio of approximately 1.18 for atopic dermatitis per T allele. The three signals were statistically independent (conditionally significant after accounting for each other), indicating they tag distinct regulatory mechanisms at the CTSS locus.

Animal model evidence directly links CTSS overexpression to atopic dermatitis-like disease. Kim et al. (Journal of Investigative Dermatology, 2012)⁵⁵ Kim et al. (Journal of Investigative Dermatology, 2012) generated CTSS-overexpressing transgenic mice that spontaneously develop chronic skin disease resembling atopic dermatitis. The phenotype was driven by PAR-2 upregulation in dendritic cells, which promoted CD4+ T cell differentiation and induced scratching behaviour alongside altered Th1/Th2 cytokine profiles. This experiment established that excess CTSS activity alone — in the absence of any external allergen — is sufficient to produce atopic dermatitis pathology through immune cell activation.

The itch mechanism was characterised in detail by Chung et al. (Neurobiology of Pain, 2019)⁶⁶ Chung et al. (Neurobiology of Pain, 2019). Intradermal injection of recombinant cathepsin S induced dose-dependent scratching in mice via PAR2 on TRPV1-expressing sensory neurons; TRPV1 knockout reduced scratching by 50% and PAR2 antagonists abolished it completely. This confirms that cathepsin S operates as a molecular pruritogen — an itch-triggering signal released by activated skin antigen-presenting cells — entirely separate from its role in antigen presentation.

Beyond atopic dermatitis, elevated CTSS expression is mechanistically linked to systemic autoimmunity. Rupanagudi et al. (Annals of the Rheumatic Diseases, 2015)⁷⁷ Rupanagudi et al. (Annals of the Rheumatic Diseases, 2015) demonstrated that selective CTSS inhibition prevents lupus nephritis in mice, confirming that this protease is non-redundant for MHC class II-driven autoantibody production. Thanei et al. (Biochemical Pharmacology, 2017)⁸⁸ Thanei et al. (Biochemical Pharmacology, 2017) showed that CatS inhibition in SLE patient-derived macrophages reduces IL-6, TNFα, and IL-10 secretion and decreases MHC class II surface expression on B cells and monocytes.

Practical Actions

For T allele carriers, the actionable insights focus on the two downstream consequences of altered CTSS activity: amplified skin antigen presentation (reducing antigen entry limits the downstream immune activation), and direct PAR2/TRPV1-mediated itch (distinct from histamine pathways and requiring different treatment targeting). The OR of 1.18 represents a modest individual risk increase, but its biological specificity — pointing to a protease with both antigen-presentation and direct pruritogenic roles — informs management more precisely than generic atopic risk.

Interactions

rs115161931 is one of three independent signals at the CTSS locus for atopic dermatitis (alongside rs187080438 and rs146527530). Co-carriage of risk alleles at multiple CTSS locus signals compounds the individual effect additively; the three signals represent distinct regulatory mechanisms acting on the same gene rather than the same functional change. Within the broader atopic architecture, CTSS acts downstream of epithelial barrier genes (FLG, SPINK5) — antigen penetration through a defective barrier is amplified by elevated CTSS-driven antigen presentation. Individuals carrying both barrier-gene variants and CTSS-locus risk alleles face a dual hit: more antigen getting in and a more sensitive presentation machinery acting on it.

The heart's ability to contract and relax is governed by molecular machines called sarcomeres — the repeating structural units of cardiac muscle fibers. One of their key regulatory proteins is cardiac myosin-binding protein C (cMyBP-C)¹¹ cardiac myosin-binding protein C (cMyBP-C)
Encoded by MYBPC3 on chromosome 11; a large (~150 kDa) modular protein that tethers the thick (myosin) filament and acts as a spring-loaded brake on myosin motor activity. The rs11570112 variant — a C-to-T change on the coding strand (plus-strand: G>A) at position 2,992 of the MYBPC3 transcript — creates a premature stop codon at amino acid 998 (p.Gln998Ter, also written Q998X or Gln998*). The resulting truncated mRNA is rapidly destroyed by nonsense-mediated decay (NMD)²² nonsense-mediated decay (NMD)
A cellular surveillance pathway that degrades transcripts containing premature stop codons to prevent production of potentially toxic truncated proteins, so essentially no truncated cMyBP-C protein is produced. The outcome is that one functional MYBPC3 allele must supply all of the protein — and in many carriers, this is not enough.

This variant is classified as Pathogenic in ClinVar³³ Pathogenic in ClinVar
VCV000180993; criteria provided, multiple submitters, no conflicts; last evaluated October 2023 for hypertrophic cardiomyopathy (HCM). It is one of hundreds of individually rare truncating MYBPC3 variants; collectively, truncating MYBPC3 mutations account for approximately 50% of all identified HCM-causing mutations, making MYBPC3 the most commonly mutated gene in this condition.

The Mechanism

cMyBP-C functions as a molecular brake on myosin motor activity. It holds myosin heads in a super-relaxed state (SRX)⁴⁴ super-relaxed state (SRX)
An energy-conserving "parked" configuration of myosin heads — the SRX minimizes ATP consumption between heartbeats and limits the fraction of motors available for active contraction during diastole, preventing excessive contractility. The Gln998X stop-gain creates a transcript that is degraded before translation, eliminating ~80% of the C-terminal domain. As Toepfer et al. demonstrated in Science Translational Medicine⁵⁵ Toepfer et al. demonstrated in Science Translational Medicine
PMID 30674652; iPSC-derived cardiomyocytes and cardiac muscle fiber experiments from the Seidman laboratory at Harvard, stepwise reduction of cMyBP-C protein causes reciprocal augmentation of myosin contractility — the brake is weakened and more myosin motors are released from the SRX into the active pool.

Human cardiac tissue studies confirm the mechanism directly: Marston et al., Circulation Research, 2009⁶⁶ Marston et al., Circulation Research, 2009
n=37 surgical myectomy samples from HCM patients and donor controls measured MyBP-C protein levels in myofibrils from patients carrying MYBPC3 mutations and found a significant ~24% reduction versus controls (p<0.0005), with no detectable truncated peptides — confirming haploinsufficiency, not a poison-peptide mechanism. The consequence at the organ level is pathological hypertrophy: the overactive sarcomeres trigger compensatory thickening of the ventricular wall, which ultimately impairs relaxation, stiffens the chamber, and can progress to outflow tract obstruction or arrhythmia.

The Evidence

Penetrance for MYBPC3 pathogenic variants is substantial but incomplete and age-dependent. A key European cohort study (Michels et al., European Heart Journal, 2009⁷⁷ Michels et al., European Heart Journal, 2009
PMID 19666645; 76 mutation carriers from 32 families, mean age 42 years) found that 41% of MYBPC3 mutation carriers had diagnosable HCM on cardiac imaging. Importantly, MYBPC3 carriers develop overt disease at an older age than MYH7 carriers (p=0.01) — a well-replicated observation suggesting a more gradual haploinsufficiency mechanism compared to the dominant-negative effects of most MYH7 missense mutations. Male carriers manifested disease earlier and more frequently than female carriers (p=0.04).

Functional experiments with engineered heart tissue⁸⁸ engineered heart tissue
PMID 27108529; Wijnker et al., 2016, using human iPSC-derived cardiomyocytes assembled into 3D cardiac constructs established a protein-level threshold: haploinsufficiency only impairs contractile function when cMyBP-C falls below approximately 73% of normal levels. Because truncating variants provide no functional protein from the mutant allele, the entire burden falls on the wild-type allele, and many carriers do fall below this threshold — particularly under cardiac stress. A mouse haploinsufficiency model (Barefield et al., JMCC, 2015⁹⁹ Barefield et al., JMCC, 2015
PMID 25463273) confirmed that heterozygous MYBPC3-truncation animals develop exacerbated hypertrophy and reduced ejection fraction when subjected to pressure overload, with myofilament cMyBP-C content dropping significantly below that of stressed wild-type animals.

The Gln998X nonsense-mediated mRNA degradation pathway is well established: Helms et al. 2014¹⁰¹⁰ Helms et al. 2014
PMID 25031304; Circulation: Cardiovascular Genetics showed that truncating MYBPC3 mutations produce mutant:wild-type mRNA ratios of approximately 1:5, consistent with efficient NMD, versus 1:1 for missense mutations. Total MYBPC3 mRNA increases ~9-fold as a compensatory response, but full-length protein levels remain reduced and no truncated peptides accumulate.

Practical Implications

A positive result for this pathogenic variant requires proactive clinical management even in the absence of symptoms, because HCM can present first as sudden cardiac death — especially during intense physical exertion. The 2024 AHA/ACC HCM guidelines (Ommen et al., Circulation, 2024¹¹¹¹ Ommen et al., Circulation, 2024
PMID 38718139) emphasize genetic cascade testing of first-degree relatives, regular echocardiographic surveillance of carriers, and individualized sudden cardiac death risk stratification. All carriers should be evaluated by a cardiologist with HCM expertise; echocardiography at the time of diagnosis and at regular intervals thereafter is the standard of care.

High-intensity competitive sport should be approached with extreme caution. For carriers who develop obstructive HCM, septal reduction therapy (surgical myectomy or alcohol septal ablation) can relieve outflow tract obstruction, and the novel cardiac myosin inhibitor mavacamten (targeting the same myosin overactivation pathway identified in laboratory studies) is now guideline-approved for symptomatic obstructive HCM.

Interactions

MYBPC3 Gln998X does not act in isolation. Modifier loci — particularly variants in renin-angiotensin-aldosterone pathway genes — influence the extent of fibrosis and hypertrophy in MYBPC3 variant carriers. Compound heterozygosity for two MYBPC3 variants (one in each allele) has been reported in Japanese HCM cohorts (PMID 22112859) and produces a more severe phenotype, effectively eliminating all functional cMyBP-C and mimicking the homozygous knockout phenotype seen in mice. Thin-filament HCM variants (TPM1 E180G, rs104894502¹²¹² TPM1 E180G, rs104894502; TNNT2 variants, rs36211723¹³¹³ TNNT2 variants, rs36211723) that independently increase Ca²⁺ sensitivity could compound with MYBPC3 haploinsufficiency through additive sarcomere overactivation, though the specific combination of Gln998X with thin-filament variants has not been studied in a published cohort.

Cryptochrome 2 (CRY2) is a core component of the molecular circadian clock¹¹ molecular circadian clock
The transcription-translation feedback loop that generates ~24-hour rhythms in virtually every cell, governing sleep-wake cycles, hormone release, and metabolism. Like its partner CRY1, CRY2 acts as a transcriptional repressor that shuts down the CLOCK:BMAL1 complex — but CRY2 has a distinct role in metabolism. The rs11605924 variant was identified in the landmark MAGIC consortium GWAS²² MAGIC consortium GWAS
Meta-analysis of 21 genome-wide association studies in 46,186 non-diabetic participants as one of nine new loci associated with fasting glucose, placing CRY2 at the intersection of circadian biology and metabolic disease.

The Mechanism

CRY2 encodes a flavin adenine dinucleotide (FAD)-binding protein³³ flavin adenine dinucleotide (FAD)-binding protein
The FAD cofactor is essential for CRY2's light-independent repressor function in mammals, distinguishing it from light-sensing cryptochromes in other organisms that forms repressive complexes with PER proteins to suppress CLOCK:BMAL1-driven transcription. This feedback loop generates rhythmic expression of thousands of metabolic genes, including those controlling hepatic glucose production⁴⁴ hepatic glucose production
CRY proteins directly regulate gluconeogenic gene expression through interaction with the glucocorticoid receptor and FOXO1 transcription factors and insulin secretion.

The rs11605924 variant sits within an intron of CRY2 on chromosome 11. While intronic, the variant appears to affect CRY2 expression or splicing efficiency, as carriers show measurable differences in both glucose homeostasis and hepatic lipid handling. CRY2 is expressed rhythmically in the liver, pancreatic beta cells, and adipose tissue, all key sites of glucose regulation.

A fascinating finding links this variant to hepatic metabolism: Machicao et al. 2016⁵⁵ Machicao et al. 2016
Machicao F et al. Glucose-Raising Polymorphisms in the Human Clock Gene Cryptochrome 2 (CRY2) Affect Hepatic Lipid Content. PLoS One, 2016 showed that the glucose-raising alleles concomitantly reduced liver fat content by approximately 30%, suggesting that the variant redirects intermediary metabolites from hepatic triglyceride synthesis toward gluconeogenesis. This metabolic shunting effect explains how the same variant can raise fasting glucose while paradoxically reducing fatty liver.

The Evidence

The MAGIC consortium GWAS⁶⁶ MAGIC consortium GWAS
Dupuis J et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet, 2010 identified rs11605924 among nine new fasting glucose loci in a meta-analysis of 46,186 non-diabetic individuals, with follow-up in 76,558 additional subjects. CRY2 was the only core circadian clock gene among these loci, providing the first direct genetic link between the circadian machinery and population-level glucose variation.

The GLACIER Study⁷⁷ GLACIER Study
Renstrom F et al. Season-dependent associations of circadian rhythm-regulating loci and glucose homeostasis. Diabetologia, 2015 from northern Sweden revealed a remarkable finding: the association between rs11605924 and 2-hour glucose levels (beta = 0.07 mmol/L per A allele, P = 0.0008, n = 9,605) was present only during the dark season (P for interaction = 0.006). During the light season, no association was detected. This season-dependent effect is biologically plausible: CRY2 is a light-responsive clock protein, and extreme photoperiod variation in northern latitudes may unmask its metabolic effects.

In the hepatic lipid study⁸⁸ hepatic lipid study
Machicao et al. 2016, four CRY2 SNPs including rs11605924 showed study-wide significant associations with fasting glucose (P < 0.0005) and concomitant associations with liver fat content (P < 0.015) in 1,715 non-diabetic individuals. In vivo MRS measurements in 375 subjects confirmed approximately 30% reduced liver fat in carriers of the glucose-raising alleles.

Replication in non-European populations came from Liu et al. 2011⁹⁹ Liu et al. 2011
Liu C et al. Variants in GLIS3 and CRY2 Are Associated with Type 2 Diabetes and Impaired Fasting Glucose in Chinese Hans. PLoS One, 2011, where the A allele was associated with combined impaired fasting glucose and type 2 diabetes (OR 1.15, 95% CI 1.01-1.30, P = 0.04) in 3,210 Chinese participants, though this association was attenuated after adjustment for additional confounders.

The POUNDS LOST Trial¹⁰¹⁰ POUNDS LOST Trial
2014 demonstrated that CRY2 rs11605924 influenced metabolic responses to weight-loss diets, with significant associations between genotype and changes in respiratory quotient, resting metabolic rate, and energy expenditure during a 2-year intervention, suggesting the variant modulates how effectively different dietary strategies work.

Practical Implications

The CRY2 variant affects glucose regulation through a circadian mechanism, which means its metabolic consequences are amplified by circadian disruption — shift work, irregular meal timing, jet lag, or insufficient light exposure. Carriers of the risk allele who maintain regular circadian rhythms may show minimal glucose elevation, while those with disrupted rhythms may see larger effects.

The seasonal modulation of the glucose effect suggests that latitude and light exposure are modifiers. People in northern latitudes carrying the A allele may benefit from light therapy during dark winter months to stabilize their circadian-metabolic coupling.

Interactions

CRY2 operates in the same circadian feedback loop as CRY1 (rs2287161), CLOCK (rs1801260), and MTNR1B (rs10830963). The GLACIER Study tested interactions between these loci and found season-dependent effects for all three circadian variants (CRY1, CRY2, MTNR1B), suggesting they converge on a shared photoperiod-sensitive metabolic pathway. Carriers of glucose-raising alleles at multiple circadian loci may show amplified seasonal glucose variation.

Compound implication for CRY2 rs11605924 + MTNR1B rs10830963: Both variants affect circadian glucose regulation — MTNR1B through melatonin-mediated suppression of insulin secretion, CRY2 through transcriptional control of gluconeogenic genes. Carriers of the risk allele at both loci may show the strongest seasonal glucose fluctuation and the greatest benefit from stabilizing circadian rhythms during dark months. They should consider monitoring fasting glucose in both summer and winter to detect seasonal variation.

The IL23R¹¹ IL23R
interleukin-23 receptor gene, chromosome 1p31.3; encodes the ligand-binding subunit of the IL-23 receptor complex that pairs with IL-12Rβ1 on Th17 cells, NK cells, and innate lymphoid cells gene has yielded multiple independent susceptibility variants for psoriatic disease, and rs12044149 is one of the most instructive. Unlike the well-known intronic IL23R variants that associate broadly with psoriasis, psoriatic arthritis, and inflammatory bowel disease, rs12044149-T shows a strikingly specific enrichment for psoriatic arthritis²² psoriatic arthritis
a chronic inflammatory arthritis affecting up to 30% of people with psoriasis, characterized by synovitis, enthesitis, dactylitis, and progressive joint damage; distinct from rheumatoid arthritis in its asymmetric distribution and nail/skin involvement over cutaneous-only psoriasis — suggesting that variation in IL-23 receptor regulation at this upstream locus differentially modulates joint versus skin inflammatory programs.

The Mechanism

rs12044149 sits at GRCh38 chr1:67,135,003, approximately 3.6 kb upstream of the IL23R transcription start site, within an intron of the poorly-characterized C1orf141 gene. Its position in the regulatory landscape of IL23R makes it a candidate cis-regulatory variant³³ cis-regulatory variant
a variant that affects expression or splicing of a nearby gene in cis (same chromosome), typically by altering transcription factor binding sites, enhancer activity, or chromatin accessibility in the locus that subtly modulates IL23R expression or activity at the joint-specific immune interface.

IL-23R signals through JAK2 and STAT3⁴⁴ JAK2 and STAT3
Janus kinase 2 and Signal Transducer and Activator of Transcription 3 — the immediate downstream effectors of IL-23 receptor engagement; pSTAT3 drives expression of RORγt, the master Th17 transcription factor to expand and sustain Th17 cell populations. In psoriatic arthritis, IL-23-stimulated Th17 cells produce IL-17A and IL-17F at the synovial interface, promoting: - RANKL-mediated osteoclast activation and bone erosion - Synoviocyte hyperplasia and pannus formation - Entheseal inflammation (tendon/ligament insertions — a hallmark of PsA) - Dactylitis ("sausage digits") from combined synovial and periarticular inflammation

The articular specificity of rs12044149-T likely reflects the distinct cytokine milieu of synovial tissue versus the epidermis. Synovial dendritic cells and macrophages may amplify IL-23 signals differently from skin-resident cells, and a variant that shifts IL23R expression even modestly at this joint-specific interface could selectively tip the balance toward arthritis over skin plaque formation.

The Evidence

The initial identification of rs12044149 came from a landmark GWAS meta-analysis comparing psoriatic arthritis to cutaneous-only psoriasis⁵⁵ landmark GWAS meta-analysis comparing psoriatic arthritis to cutaneous-only psoriasis
Stuart et al. 2015, American Journal of Human Genetics; 9,293 psoriasis-spectrum case subjects, 3,061 PsA cases, 3,110 cutaneous-only psoriasis cases, 13,670 controls, all European descent. This study was specifically designed to dissect the genetics of the PsA/PsC split. The rs12044149-T allele near IL23R reached p = 0.00018 with stronger association in PsA than PsC, and crucially, this signal was independent of the previously identified psoriasis variants at the IL23R locus (notably rs2201841) — meaning rs12044149 tags a distinct component of IL23R biology relevant specifically to arthritis development.

The association was substantially strengthened in a large-scale comparative genetic analysis⁶⁶ large-scale comparative genetic analysis
Soomro et al. 2022, Arthritis & Rheumatology; 5,065 PsA patients, 21,286 healthy controls, and 6,431 cutaneous-only psoriasis patients, which confirmed the rs12044149-T association with PsA at p = 4×10⁻²⁰, OR 1.27 (95% CI 1.20–1.33). A risk allele frequency of 0.26 in this study is consistent with the global T allele frequency of ~24%. The genome-wide significance and large sample size places this association firmly in the strong evidence tier.

The broader IL23R locus context is established by meta-analyses of IL23R variants⁷⁷ meta-analyses of IL23R variants
Zhu et al. 2012, Inflammation Research — 13 studies confirming IL23R association with psoriasis and PsA: the IL-23 pathway is one of the most genetically validated axes in psoriatic disease, and rs12044149 adds to this locus by tagging the articular-specific component that other IL23R variants do not fully capture.

Practical Actions

The primary clinical significance of rs12044149-T is as an early-warning marker for psoriatic arthritis risk, particularly in individuals who already have — or are at risk for — cutaneous psoriasis. An OR of 1.27 per T allele means TT homozygotes (roughly 6% of Europeans) carry approximately 1.6-fold elevated PsA risk relative to GG homozygotes under an additive model.

No pharmacogenomic guideline currently links rs12044149 to differential response to IL-23 inhibitors (risankizumab, guselkumab) or IL-17 inhibitors (secukinumab, ixekizumab). However, the biological rationale for IL-23/IL-17 pathway therapies in PsA is strong, and these agents are now first-line options for active PsA with inadequate response to conventional DMARDs. The genotype contextualizes the pathway being targeted without yet predicting which specific agent will perform best.

Early detection of psoriatic arthritis matters enormously: joint damage begins within months of disease onset and is irreversible. The window between first articular symptoms and diagnosis currently averages 1.5–2.5 years — a gap that genotype-informed awareness can help close.

Interactions

rs12044149 operates in the same IL-23/Th17 corridor as several other variants in the GeneOps database. rs2201841 (IL23R, intronic) is the principal psoriasis/IBD susceptibility locus at IL23R — the two variants appear to be independent signals at the same locus, tagging different regulatory elements with different tissue emphases. The Stuart 2015 study explicitly confirmed rs12044149's independence from rs2201841 in the joint-disease signal.

rs33980500 (TRAF3IP2/Act1 D10N) is the downstream IL-17 signaling adaptor variant most strongly associated with psoriatic arthritis — its risk allele is highly specific to PsA over cutaneous psoriasis, making it a natural companion marker to rs12044149 at the receptor level. Together, they may tag individuals with both enhanced IL-23 input and heightened IL-17 downstream responsiveness in joint tissue.

rs9321623 near TNFAIP3 was co-identified in the same Stuart 2015 GWAS as a second PsA-specific locus; individuals carrying risk alleles at both rs12044149 and rs9321623 may have additive susceptibility to articular psoriatic disease through complementary NF-κB and IL-23 pathway dysregulation.

Three amino acids — lysine, arginine, and ornithine — share a specialized transport system for crossing the intestinal wall and for reabsorption in the kidney tubule. That system is y+LAT1, encoded by the SLC7A7 gene. When both copies of SLC7A7 carry loss-of-function variants, cationic amino acids cannot exit the intestinal epithelium into the bloodstream, and cannot be retrieved from urine by the kidney. The result is lysinuric protein intolerance (LPI)¹¹ lysinuric protein intolerance (LPI)
A rare autosomal recessive disorder of cationic amino acid transport; OMIM #222700. Approximately 200 cases reported globally, with the highest prevalence in Finland (1:60,000) and Japan (1:57,000) — a multisystem disorder that is manageable but not curable.

This SNP, rs121908677, captures the c.161G>T missense change (coding strand notation) that converts glycine to valine at position 54 of y+LAT1 (p.Gly54Val). On the genomic plus strand, this appears as a C>A transversion at chr14:22,813,238 (GRCh38). The variant was identified by Mykkänen et al. in 2000²² Mykkänen et al. in 2000
Mykkänen J et al. Functional analysis of novel mutations in y(+)LAT-1 amino acid transporter gene causing lysinuric protein intolerance. Hum Mol Genet, 2000 in a homozygous Latvian patient and a homozygous Estonian patient — a pattern consistent with its rarity and the geographic clustering of LPI cases around the Baltic region and Scandinavia.

The Mechanism

y+LAT1 does not work alone. It forms a heterodimer³³ heterodimer
A protein complex composed of two different subunits. y+LAT1 is the light catalytic subunit; 4F2hc (encoded by SLC3A2) is the heavy structural subunit. Together they form a functional transporter at the basolateral membrane of intestinal and renal epithelial cells with 4F2hc (encoded by SLC3A2), and this complex mediates efflux of cationic amino acids (lysine, arginine, ornithine) from the epithelial cell into the portal circulation, exchanging them for neutral amino acids plus sodium.

Glycine 54 sits in a highly conserved transmembrane region of y+LAT1. The Gly54Val substitution replaces the smallest amino acid (glycine, no side chain) with a branched-chain valine, disrupting the precise geometry of the transmembrane helix packing. Critically, the G54V mutant protein is not degraded intracellularly — it reaches the plasma membrane correctly when coexpressed with 4F2hc in the Xenopus oocyte expression system used by Mykkänen et al. — but once there, it has zero amino acid transport activity⁴⁴ zero amino acid transport activity
In contrast, frameshift mutants in the same study were trapped intracellularly and never reached the membrane. G54V thus represents a surface-displayed "dead" transporter — folded but non-functional, similar to the delta-F508 CFTR mutation in cystic fibrosis. The structural integrity is preserved; the catalytic function is destroyed.

When both SLC7A7 alleles are non-functional, cationic amino acids accumulate inside intestinal and renal epithelial cells while failing to reach the bloodstream. Plasma lysine, arginine, and ornithine are chronically depressed. Arginine and ornithine deficiency undermines the urea cycle, leading to post-prandial hyperammonemia⁵⁵ hyperammonemia
Elevated blood ammonia. The urea cycle requires ornithine and arginine as substrates; when both are scarce, ammonia cannot be adequately cleared after protein meals. Ammonia is neurotoxic even at mildly elevated levels, causing encephalopathy, coma, and permanent neurological damage if untreated after protein-rich meals. Lysine deficiency impairs collagen cross-linking, bone matrix synthesis, and immune function.

The Evidence

SLC7A7 was identified as the LPI gene simultaneously by two groups in 1999: Borsani et al. (Nature Genetics)⁶⁶ Borsani et al. (Nature Genetics)
Borsani G et al. SLC7A7, encoding a putative permease-related protein, is mutated in patients with lysinuric protein intolerance. Nat Genet, 1999 in Italian patients and Torrents et al. in Finnish and Spanish patients. Since then, more than 43 distinct pathogenic SLC7A7 mutations have been catalogued across 130 patients from 98 independent families Sperandeo et al. 2008⁷⁷ Sperandeo et al. 2008
Sperandeo MP et al. Lysinuric protein intolerance: update and extended mutation analysis of the SLC7A7 gene. Hum Mutat, 2008, with no genotype-phenotype correlations established — severity varies enormously even within families carrying identical mutations.

The functional null character of Gly54Val was established by the Mykkänen 2000 oocyte study, which tested five SLC7A7 missense mutations functionally and found that all, including G54V, abolished transport despite variable effects on membrane localization.

Systemic complications beyond hyperammonemia are well-documented. Pulmonary alveolar proteinosis (PAP)⁸⁸ Pulmonary alveolar proteinosis (PAP)
Accumulation of proteinaceous material in the alveoli, impairing gas exchange. In LPI, this is thought to result from macrophage dysfunction secondary to arginine/ornithine deficiency, with abnormal lysosomal processing of surfactant proteins. PAP can be life-threatening and does not reliably respond to citrulline supplementation occurs in a significant minority of LPI patients, sometimes from childhood, and represents the leading cause of LPI-related mortality Parto et al. 1993⁹⁹ Parto et al. 1993
Parto K et al. Pulmonary alveolar proteinosis and glomerulonephritis in lysinuric protein intolerance: case reports and autopsy findings of four pediatric patients. J Pediatr, 1993. Osteoporosis, glomerulonephritis, and hemophagocytic syndrome-like presentations are additional recognized complications.

Practical Actions

Citrulline supplementation is the cornerstone of LPI management because citrulline is a neutral amino acid — it is absorbed normally via a different transporter system — and is converted to arginine and ornithine inside hepatocytes, replenishing the urea cycle substrates that cannot enter via the defective y+LAT1 route. The landmark two-year citrulline trial¹⁰¹⁰ two-year citrulline trial
Rajantie J et al. Lysinuric protein intolerance: a two-year trial of dietary supplementation therapy with citrulline and lysine. J Pediatr, 1980 by Rajantie et al. demonstrated catch-up growth in seven of nine previously stunted children and normalization of urea cycle function. Dosing is now standardized at up to 100 mg/kg/day citrulline in 4 divided doses with meals, combined with protein restriction to 0.8-1.5 g/kg/day to limit ammonia load. Supplemental L-lysine (20-30 mg/kg/day) is added because lysine cannot be recovered adequately from urine. High-dose citrulline may paradoxically worsen nitric oxide overproduction in some patients; dosing should be supervised and individualized.

Carriers (AC genotype) are uniformly asymptomatic and require no treatment. Their significance is reproductive: if both parents carry any SLC7A7 loss-of-function variant, each child has a 25% risk of LPI.

Interactions

Because LPI is autosomal recessive, full disease expression requires biallelic SLC7A7 loss. Many LPI patients are compound heterozygous (two different SLC7A7 mutations rather than homozygous for a single one); a carrier of this G54V allele who also carries a different pathogenic SLC7A7 variant in trans would be clinically affected. Comprehensive SLC7A7 gene sequencing — not single-SNP genotyping — is required for complete clinical evaluation. The compound heterozygous scenario is relevant to the compound action system: rs121908677 AC status combined with any second SLC7A7 pathogenic allele would produce the full LPI phenotype.

The melanocortin-4 receptor (MC4R) is the brain's central appetite brake, translating signals from leptin and melanocortin hormones into "stop eating" commands. rs12970134 lies in the same regulatory region¹¹ regulatory region
intergenic DNA approximately 188 kilobases downstream of the MC4R gene that modulates its expression as the better-known rs17782313, and the two variants are in moderate-to-high linkage disequilibrium²² linkage disequilibrium
the tendency for nearby variants to be inherited together, making their effects partly overlapping in most populations. What sets rs12970134 apart is its particularly strong signal for waist circumference and insulin resistance³³ waist circumference and insulin resistance
as opposed to BMI alone, which is more influenced by rs17782313 in some study designs — making it a complementary lens on the same locus.

The 2008 discovery paper⁴⁴ 2008 discovery paper
Chambers et al., Nature Genetics identified rs12970134 through a genome-wide association scan in 2,684 Indian Asians specifically designed to find variants influencing central adiposity. Homozygotes for the A allele had approximately 2 centimeters greater waist circumference (p=1.7×10⁻⁹), and the association with insulin resistance was independent of fat mass — suggesting the MC4R locus influences glucose homeostasis through pathways beyond adiposity alone.

The Mechanism

Like rs17782313, rs12970134 is thought to act by modulating MC4R expression in hypothalamic neurons rather than changing the receptor protein itself. The MC4R receptor sits at the convergence of leptin signaling: fat cells secrete leptin, which activates POMC neurons in the arcuate nucleus⁵⁵ arcuate nucleus
a brain region in the hypothalamus that detects energy status, which release alpha-melanocyte stimulating hormone (α-MSH), which binds MC4R to suppress appetite and increase energy expenditure. When regulatory variants reduce MC4R expression, this entire cascade is dampened — fewer satiety receptors means weaker "full" signals.

The insulin resistance component is less well characterized but likely reflects the same hypothalamic pathway. MC4R-expressing neurons in the paraventricular nucleus⁶⁶ paraventricular nucleus
a key hypothalamic area coordinating energy balance and autonomic nervous system output project to peripheral tissues via the sympathetic nervous system, influencing both insulin sensitivity in muscle and liver and glucose uptake. Reduced MC4R tone may impair this central regulation of peripheral glucose metabolism independently of body weight.

The Evidence

The strongest single-SNP data come from a 14,940-person Danish cohort⁷⁷ 14,940-person Danish cohort
Zobel et al., Diabetes 2009 where rs12970134 showed the largest per-allele BMI effect among three MC4R-region variants tested: +0.31 kg/m² per A allele (p=7×10⁻⁴) and +0.85 cm per allele for waist circumference (p=3×10⁻⁴). The variant also combined additively with FTO rs9939609, so individuals carrying both MC4R and FTO risk alleles showed compound adiposity burden.

A meta-analysis of 123,373 individuals⁸⁸ meta-analysis of 123,373 individuals
Xi et al., Diabetologia 2012 confirmed the MC4R locus associates with type 2 diabetes at OR=1.10 (p=2.83×10⁻¹²), and crucially, this association remained significant after BMI adjustment (OR=1.06, p=2.14×10⁻⁵), indicating a direct metabolic effect beyond obesity-driven glucose dysregulation.

In children, 745 Caucasian schoolchildren⁹⁹ 745 Caucasian schoolchildren
Marcovecchio et al., Horm Res Paediatr 2014 showed that A allele dosage predicted both BMI standard deviation score and waist-to-height ratio progressively across GG → AG → AA genotypes, with effects emerging after age 8.3 years — suggesting the genetic influence on central adiposity accumulates through childhood growth rather than manifesting at birth.

A haplotype study Wei et al., Mol Med 2020¹⁰¹⁰ Wei et al., Mol Med 2020 found the combined rs17782313C-rs476828C-rs12970134A haplotype carries OR=1.796 for obesity (95% CI=1.447–2.229), while individual SNP effects are smaller, consistent with these variants tagging a shared underlying functional signal.

Practical Implications

The insulin resistance signal from rs12970134 means that A allele carriers face a dual challenge: increased central adiposity (waist circumference) that itself drives insulin resistance, plus a potential direct hypothalamic effect on glucose regulation. Monitoring fasting glucose and insulin is warranted, particularly as central fat accumulates with age.

Because the variant operates through reduced MC4R satiety signaling, the same behavioral levers apply as for rs17782313 — but the waist circumference phenotype means the priority shifts toward interventions that specifically reduce visceral (abdominal) fat rather than total body weight. Visceral fat is more metabolically active, drives insulin resistance more strongly than subcutaneous fat, and responds particularly well to low-glycaemic-load dietary patterns¹¹¹¹ low-glycaemic-load dietary patterns
diets that minimize rapid glucose spikes and to strength training that builds insulin-sensitive muscle mass.

Interactions

rs17782313: The most important interaction is with this neighboring MC4R-region SNP. The two variants are in moderate-to-high LD¹²¹² moderate-to-high LD
inherited together frequently, with overlapping biological effects and likely tag the same regulatory block. Carrying both risk alleles does not simply double the effect — they share substantial biological variance. The GeneOps platform evaluates them independently because they are not in perfect LD and may provide complementary information, particularly in populations where LD patterns differ (for example, South Asians have higher A allele frequency for rs12970134 at ~36% but lower C allele frequency for rs17782313, suggesting the regulatory landscape differs between populations).

FTO rs9939609: The Danish cohort confirmed additive effects when both MC4R and FTO risk alleles are present, with combined per-allele BMI impact reaching 0.43 kg/m². A Chinese pediatric study Yang et al. 2019¹³¹³ Yang et al. 2019 found individuals with risk genotypes at FTO, rs12970134, and rs17782313 together had 2.453-fold increased obesity risk (OR=2.45, 95% CI=1.12–5.37). Because FTO acts primarily through thermogenesis and MC4R through appetite, addressing both pathways simultaneously provides complementary benefit.

Endometriosis — tissue similar to the uterine lining growing outside the uterus — affects an estimated 10% of women of reproductive age and accounts for a substantial share of chronic pelvic pain and infertility. The condition is driven by estrogen¹¹ estrogen
estrogen is the primary hormonal fuel for endometriotic lesion growth; ectopic implants express elevated levels of aromatase, generating their own local estrogen supply and sustained by immune tolerance at ectopic implant sites. Roughly half of endometriosis susceptibility is heritable, and rs13394619 in GREB1 is one of the most consistently replicated common genetic risk signals discovered to date.

GREB1 — Growth Regulation by Estrogen in Breast Cancer 1 — was first identified as an early estrogen response gene in breast cancer cell lines. It encodes a nuclear co-factor that physically interacts with hormone receptors to amplify their transcriptional activity. The gene sits on chromosome 2p25.1, and rs13394619 lies in an intronic region between exons 9 and 10 with predicted effects on local splicing activity.

The Mechanism

GREB1 operates as a pan-steroid hormone cofactor²² GREB1 operates as a pan-steroid hormone cofactor
Chadchan et al. Nature Communications, 2024 that behaves differently depending on the hormonal and cellular context. In healthy endometrium during the secretory phase, GREB1 is progesterone-responsive: it physically binds the progesterone receptor and amplifies expression of downstream targets including WNT4 and FOXO1A, which drive the stromal decidualization required for embryo implantation.

In endometriotic lesions the circuit flips. Ectopic tissue accumulates estrogen through locally upregulated aromatase, and in this estrogen-dominant environment GREB1 switches to functioning as an estrogen receptor cofactor — amplifying estrogen-driven gene expression and proliferation of ectopic cells. Mouse models with GREB1 knockout show significantly reduced endometriotic lesion volume and mass. Human endometriotic cells with GREB1 knockdown proliferate more slowly when exposed to estrogen.

The intronic rs13394619 variant may influence how GREB1 is spliced or expressed in endometrial tissue. Although eQTL analyses have not identified a single dramatically altered transcript, fine-mapping studies have identified multiple nearby variants with stronger individual associations, suggesting the region contains regulatory elements relevant to endometrial gene expression. GREB1 mRNA and protein are significantly elevated in peritoneal endometriotic lesions compared with eutopic endometrium from unaffected women³³ GREB1 mRNA and protein are significantly elevated in peritoneal endometriotic lesions compared with eutopic endometrium from unaffected women
Pellegrini et al. Fertility and Sterility, 2012, supporting GREB1 as a functionally active contributor to estrogen-dependent lesion growth.

The Evidence

rs13394619 was identified in a genome-wide association meta-analysis of 4,604 endometriosis cases and 9,393 controls of Japanese and European ancestry⁴⁴ genome-wide association meta-analysis of 4,604 endometriosis cases and 9,393 controls of Japanese and European ancestry
Nyholt et al. Nature Genetics, 2012. The G allele reached genome-wide significance (OR 1.15, 95% CI 1.09–1.20, P = 6.1 × 10⁻⁸) in the combined analysis, with consistent direction of effect across all contributing cohorts.

A subsequent meta-analysis of eight GWAS datasets encompassing European and Japanese populations⁵⁵ meta-analysis of eight GWAS datasets encompassing European and Japanese populations
Rahmioglu et al. Human Reproduction Update, 2014 confirmed the association: OR 1.13 (95% CI 1.07–1.20, P = 2.9 × 10⁻⁸). Notably, five of the six confirmed endometriosis loci — including the GREB1 locus — showed stronger effects when restricted to Stage III/IV (moderate-to-severe) disease, with the Stage III/IV enriched estimate for rs13394619 reaching P = 3.5 × 10⁻⁸ and OR = 1.15.

Independent replication in a Belgian cohort of 998 cases and 783 controls⁶⁶ Belgian cohort of 998 cases and 783 controls
Sapkota et al. Twin Research and Human Genetics, 2015 confirmed nominally significant association, which reached genome-wide significance in the updated meta-analysis. The G allele frequency shows marked ancestry stratification: approximately 0.51 in Europeans and 0.50 in East Asians, but only approximately 0.14 in African populations.

Practical Implications

Carrying G alleles at rs13394619 raises the population-level probability of developing endometriosis, with the greatest estimated effect on moderate-to-severe disease. The absolute risk added by a single common variant of this effect size (OR ~1.13–1.15 per allele) is modest, but the biological pathway — GREB1's estrogen-driven amplification of ectopic tissue growth — points to concrete surveillance and specialist engagement strategies.

The most actionable implication is awareness of cardinal symptoms and willingness to escalate evaluation early. Endometriosis average diagnostic delay remains approximately 7–9 years in many healthcare systems. Severe dysmenorrhea, deep dyspareunia, cyclic bowel or bladder symptoms, and unexplained infertility are the key presentations to act on rather than normalize.

For GG homozygotes — who carry the highest common genetic load at this locus — the elevated probability of moderate-to-severe disease specifically supports proactive fertility counseling, early ovarian reserve assessment, and lower thresholds for specialist referral if symptoms emerge.

Interactions

rs12700667 (7p15.2, near HOXA10/HOXA11): rs12700667 is the other major replicated endometriosis GWAS locus, operating through a distinct candidate pathway — long-range regulation of homeobox genes that orchestrate endometrial development and receptivity. While formal statistical interaction testing between rs13394619 and rs12700667 has not been published, both variants show independent additive genome-wide significant effects on endometriosis risk, both show stronger effects for Stage III/IV disease, and women carrying risk alleles at both loci may represent a subgroup with substantially elevated cumulative susceptibility.

For a supervisor compound action proposal: women carrying the G risk allele at rs13394619 (GG or AG) AND the A risk allele at rs12700667 (AA or AG) carry the two strongest and most replicated common endometriosis GWAS signals simultaneously. The combined recommendation would be: lower threshold for specialist gynecological referral for any pelvic symptoms, earlier baseline ovarian reserve testing (AMH + antral follicle count), and proactive fertility counseling by age 28–30. Evidence level: moderate (both loci independently established; combined effect inferred from consistent additive direction rather than formal interaction analysis).

rs11674184 (GREB1): A second intronic GREB1 variant also associated with endometriosis risk. Studies in Greek populations testing rs11674184 as a proxy for the GREB1 locus found non-significant results in a small cohort, illustrating the population-level heterogeneity in this region. Both variants lie within GREB1 and may tag overlapping haplotypes.

Inside the neurons that govern hunger and body weight in the hypothalamus, a tiny hair-like structure called the primary cilium¹¹ primary cilium
A single immotile antenna-like projection found on most cells, used for signal reception rather than movement; distinct from motile cilia in airways serves as the master receiver for satiety hormones. The ADCY3 gene encodes adenylyl cyclase 3²² adenylyl cyclase 3
An enzyme embedded in the ciliary membrane that converts ATP into cyclic AMP (cAMP), a second messenger that amplifies hormonal signals from leptin, melanocortins, and other satiety factors, a critical signal amplifier that translates incoming satiety messages into cellular responses that suppress appetite and increase energy expenditure. rs13407913 is a common intronic variant in ADCY3 sitting within the broader ADCY3-DNAJC27 genomic locus that has been linked to body mass index across multiple large GWAS studies.

The Mechanism

ADCY3 is selectively concentrated in the primary cilia of hypothalamic neurons, including those in the arcuate, ventromedial, paraventricular, and suprachiasmatic nuclei — the core appetite-regulating regions of the brain. When leptin or melanocortin-4 receptor (MC4R)³³ melanocortin-4 receptor (MC4R)
A G-protein-coupled receptor in hypothalamic neurons activated by the satiety peptide alpha-MSH, signaling fullness and suppressing food intake agonists activate their respective G-protein-coupled receptors on ciliary membranes, ADCY3 generates cAMP within the cilium. This local cAMP pulse drives intracellular signaling cascades that reduce food intake and promote energy expenditure.

Loss-of-function mutations in ADCY3 — whether engineered in mice, naturally occurring in Greenlandic Inuit populations (splice variant c.2433-1G>A), or identified in rare variant screens of diverse ancestries — consistently produce severe obesity. The mechanism is failure of hypothalamic neurons to properly transduce satiety signals: hormones bind and receptors activate, but without ADCY3 in the cilium, the cAMP pulse that would normally dampen appetite does not occur. The c.2433-1G>A splice variant⁴⁴ c.2433-1G>A splice variant
Disrupts a splice acceptor site, causing exon skipping and intron retention, reducing overall ADCY3 RNA and protein expression in carriers found in Greenlandic Inuit was among the first human loss-of-function variants shown to markedly increase obesity risk through this ciliary pathway.

rs13407913 is an intronic variant located at position c.676-2056 in the ADCY3 transcript — approximately 2,056 nucleotides from exon 676. Intronic variants at this distance from exon boundaries rarely affect splicing directly, but may influence gene expression through regulatory element effects or linkage with other functional variants in the region. The ADCY3-DNAJC27 locus⁵⁵ ADCY3-DNAJC27 locus
A genomic region on chromosome 2p23.3 containing ADCY3 and the adjacent chaperone gene DNAJC27; methylation changes at this locus suppress expression of both genes, increasing BMI risk has been robustly associated with BMI across populations.

The Evidence

The first functional human evidence came from a childhood GWAS by Stergiakouli et al. 2014⁶⁶ Stergiakouli et al. 2014
Genome-wide association study of height-adjusted BMI in childhood identifies functional variant in ADCY3. Obesity (Silver Spring), 2014; n=5,809 children from ALSPAC, replicated in Generation R which identified a missense variant at the ADCY3 locus (rs11676272) strongly associated with height-adjusted BMI (0.28 kg/m³·¹ per G allele, p = 6 × 10⁻⁹), driven by an expression QTL: the risk allele correlates with reduced ADCY3 mRNA levels. This established that common ADCY3 variation affects gene expression and child BMI.

The biological case was strengthened by Grarup et al. 2018⁷⁷ Grarup et al. 2018
Loss-of-function variants in ADCY3 increase risk of obesity and type 2 diabetes. Nature Genetics, 2018; Greenlandic cohort with replication across trans-ancestry groups, which identified the Greenlandic splice variant (c.2433-1G>A) as markedly increasing obesity and type 2 diabetes risk by disrupting ADCY3 RNA expression. The paper also found enrichment of rare ADCY3 loss-of-function variants among T2D cases in trans-ancestry cohorts, supporting a causal role across populations. A review by Andersen & Hansen 2018⁸⁸ Andersen & Hansen 2018
Genetics of metabolic traits in Greenlanders: lessons from an isolated population. J Intern Med, 2018 confirmed the mechanism: reduced ADCY3 function causes obesity through disrupted primary cilia signaling in the hypothalamus.

Cross-species evidence is consistent: ADCY3-deficient mice are obese, and a 2023 study in Labrador Retrievers identified an intronic ADCY3 deletion associated with 5.56 kg higher body weight per allele⁹⁹ 5.56 kg higher body weight per allele
Among the largest per-allele weight effects ever mapped in a canine GWAS, showing that ADCY3 dosage effects on body weight are conserved across mammals.

For rs13407913 specifically, no published study has reported an independent association or functional characterization of this intronic variant. It resides within the ADCY3 gene and likely tags nearby functional variation through linkage disequilibrium. The population frequency pattern — G allele much more common in Africans (~79%) than Europeans (~43%) — suggests ancestral diversity and population differentiation that could reflect local selection on ADCY3 expression levels.

Practical Actions

ADCY3 function in hypothalamic cilia is central to how your brain registers fullness after meals. When ADCY3-mediated cAMP signaling is reduced, satiety hormones (leptin, alpha-MSH) bind their receptors but the downstream signal is attenuated — appetite suppression is weaker and the drive to eat persists longer than it should. This is a central mechanism, distinct from insulin resistance or adipose tissue thermogenesis deficits.

For carriers of the G allele at rs13407913, the practical implications are modest and uncertain at the level of this specific variant. The broader ADCY3 biology, however, points to two strategies: supporting ciliary signaling through adequate sleep (cilia are most functional in well-rested hypothalamic neurons), and reducing environmental factors that blunt leptin sensitivity (chronic sleep deprivation, ultra-processed food palatability signals). Emerging evidence also suggests that GLP-1 receptor agonists may partially bypass the ciliary cAMP step in hypothalamic satiety signaling.

Interactions

rs13407913 is within the same gene as rs11676272, the missense variant that drives the established ADCY3 BMI association. Whether rs13407913 is in LD with rs11676272 or represents an independent signal has not been determined in published literature.

ADCY3 ciliary signaling intersects with the leptin receptor pathway (LEPR, rs1137101) — a dysfunctional leptin receptor reduces the upstream signal that ADCY3 would amplify, and impaired ADCY3 reduces the ability to transduce even a normal leptin signal. The functional overlap is biological rather than a documented statistical interaction.

The FTO locus (rs9939609) affects adipocyte thermogenesis via IRX3/IRX5, a distinct mechanism from ADCY3's hypothalamic ciliary role. Individuals carrying risk alleles at both loci would face both peripheral (reduced thermogenesis) and central (impaired satiety signaling) contributors to positive energy balance.

The 9p21.3 locus on chromosome 9 is the most replicated common genetic risk region for coronary artery disease (CAD) ever identified — and it doubles as a susceptibility locus for periodontitis. rs1360590 sits within an intron of CDKN2B-AS1 (ANRIL)¹¹ CDKN2B-AS1 (ANRIL)
Antisense Non-coding RNA in the INK4 Locus — a long non-coding RNA transcribed antisense to the tumor suppressor genes CDKN2A and CDKN2B at chromosome 9p21.3, one of several tag SNPs at this locus validated for both cardiovascular and periodontal disease risk.

The C allele at rs1360590 was identified as a susceptibility variant for aggressive and chronic periodontitis in two independent European cohorts²² two independent European cohorts
Schaefer AS et al. CDKN2BAS is associated with periodontitis in different European populations and is activated by bacterial infection. J Med Genet. 2011;48(1):38-47.. The same chromosomal region had previously been shown to confer shared risk for coronary heart disease and aggressive periodontitis — diseases linked by chronic systemic inflammation.

The Mechanism

ANRIL operates as a master regulator of the CDKN2A/CDKN2B gene cluster, which encodes the cyclin-dependent kinase inhibitors p16-INK4a and p15-INK4b. These proteins control cellular senescence — when cells stop dividing after accumulating damage. The 9p21.3 risk haplotype disrupts the ANRIL regulatory architecture, impairing the balance between proliferation and senescence in vascular smooth muscle cells and macrophages³³ vascular smooth muscle cells and macrophages
Two cell types central to atherosclerotic plaque formation — VSMCs proliferate abnormally in atherogenesis, while macrophages drive inflammatory plaque instability.

ANRIL exists in two molecular forms with opposing effects. Linear ANRIL interacts with the transcription factor YY1 to upregulate pro-inflammatory cytokines⁴⁴ upregulate pro-inflammatory cytokines
Including IL-6 and IL-8 — key mediators of systemic and vascular inflammation that promote atherosclerosis and periodontal tissue destruction. Circular ANRIL (circANRIL), by contrast, is protective: it binds the ribosomal assembly factor PES1, inducing nucleolar stress and p53-mediated apoptosis in vascular cells⁵⁵ inducing nucleolar stress and p53-mediated apoptosis in vascular cells
circANRIL suppresses smooth muscle cell proliferation, a key atherogenic process; the ratio of circANRIL to linear ANRIL inversely correlates with coronary stenosis severity. Risk variants at this locus shift the balance toward linear ANRIL, tilting cells toward a pro-inflammatory, pro-proliferative state.

A critical functional finding is that oral bacterial challenge powerfully induces ANRIL. Stimulation of gingival fibroblasts with Porphyromonas gingivalis⁶⁶ Porphyromonas gingivalis
The primary periodontal pathogen — a Gram-negative anaerobe that invades gingival tissue and triggers systemic inflammatory responses extending beyond the oral cavity increased CDKN2BAS expression 25-fold in human gingival fibroblasts and 4-fold in gingival epithelial cells. This demonstrates that C-allele carriers are not just constitutively primed for inflammatory signaling — they are also acutely vulnerable to oral bacterial infection as an ANRIL amplifier.

The Evidence

The initial 9p21.3 association with aggressive periodontitis and CHD was established by Schaefer et al. (2009)⁷⁷ Schaefer et al. (2009)
Identification of a shared genetic susceptibility locus for coronary heart disease and periodontitis. PLoS Genetics., who identified the lead SNP rs1333048 with OR 1.99 (95% CI 1.33–2.94, p=6.9×10⁻⁴) for generalized aggressive periodontitis — a finding that simultaneously placed this locus as a shared causal region for two of the most prevalent inflammatory diseases globally.

rs1360590 was among three tag SNPs subsequently validated across Dutch and German cohorts (combined n=1,577)⁸⁸ validated across Dutch and German cohorts (combined n=1,577)
Schaefer AS et al., J Med Genet 2011, aggressive and chronic periodontitis; validated after adjustment for smoking, gender, and diabetes for both aggressive and chronic periodontitis. An independent replication in 469 individuals⁹⁹ 469 individuals
Ernst et al. BMC Med Genet 2010 — independent case-control cohort with meta-analysis; confirmed 9p21.3 association with generalized aggressive periodontitis further confirmed the 9p21.3 periodontitis association using overlapping tag SNPs.

The mechanistic link to cardiovascular risk was elucidated through circANRIL biology: higher circANRIL expression is associated with the protective 9p21.3 haplotype, while risk variants show relatively less circANRIL and more linear ANRIL — translating to greater vascular inflammation and less apoptotic regulation in plaques. The circANRIL-to-linear ANRIL ratio inversely correlates with coronary artery stenosis severity in human patients¹⁰¹⁰ inversely correlates with coronary artery stenosis severity in human patients
Holdt LM et al. Nat Commun 2016; the ratio measured in circulating blood cells reflected disease state.

Practical Actions

For C-allele carriers, two distinct risk pathways require attention: the oral inflammatory gateway (periodontitis–ANRIL induction–systemic inflammation) and the direct vascular senescence pathway shared with the broader 9p21.3 haplotype.

The most genotype-specific intervention is rigorous periodontal hygiene and monitoring. Bacterial infection is a documented ANRIL amplifier — P. gingivalis specifically upregulates CDKN2BAS expression 25-fold in gingival tissue. This is not general dental advice; it is a genotype-specific inflammatory control strategy. C-allele carriers who develop periodontal disease are not merely risking tooth loss — they are activating an ANRIL-mediated systemic inflammatory cascade that shares a molecular pathway with coronary artery disease risk.

Cardiovascular monitoring with inflammatory biomarkers — specifically high-sensitivity CRP and lipid panels — is appropriate given the shared locus biology. The 9p21.3 haplotype that rs1360590 tags is the strongest common genetic signal for CAD in humans.

Interactions

rs1360590 is in linkage disequilibrium with other 9p21.3 risk variants including rs4977574 and rs1333049 (primary CAD-associated SNPs) and rs2811712 (ANRIL functional aging variant). Together these tag SNPs capture the broad 9p21.3 risk haplotype. Carriers of risk alleles across multiple 9p21.3 SNPs carry greater cumulative ANRIL dysregulation burden than any single variant predicts.

The periodontitis–CAD inflammatory link at this locus suggests a specific interaction pathway: oral bacterial dysbiosis activates ANRIL → elevated IL-6 and IL-8 → systemic pro-inflammatory state → accelerated atherosclerotic plaque instability. This mechanistic chain makes periodontal status a uniquely important modifiable variable for carriers of the 9p21.3 risk haplotype.